A Study to Evaluate Efficacy and Safety of Intravenous ACU193 in Participants With Early Alzheimer's Disease (ALTITUDE-AD) - Trial NCT06335173
Access comprehensive clinical trial information for NCT06335173 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Acumen Pharmaceuticals and is currently Recruiting. The study focuses on Alzheimer Disease. Target enrollment is 2040 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Acumen Pharmaceuticals
Timeline & Enrollment
Phase 2/3
Feb 29, 2024
Jan 01, 2031
Primary Outcome
Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score
Summary
The primary purpose of this study is to evaluate the efficacy of ACU193 infusions
 administered once every four weeks (Q4W) in slowing cognitive and functional decline as
 compared to placebo in participants with early Alzheimer's disease.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06335173
Non-Device Trial